RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V.
Nelson BE, et al. Among authors: cabanillas m.
Mol Cancer. 2024 Mar 26;23(1):64. doi: 10.1186/s12943-024-01982-4.
Mol Cancer. 2024.
PMID: 38532456
Free PMC article.